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Abstract
The use of drug combinations in clinical trials is increasingly common during the last years
since a more favorable therapeutic response may be obtained by combining drugs that, for
instance, target multiple pathways or inhibit resistance mechanisms. However, most of the
existing methodology in phase I trials recommends a single maximum tolerated dose (MTD),
which may result in a failed phase II since other MTDs may present higher treatment efficacy
for the same level of toxicity. We are motivated by a phase I/II trial that combines cisplatin
with cabazitaxel for patients with prostate cancer with visceral metastasis. We present a
Bayesian adaptive phase I/II design with drug combinations where a binary dose limiting
toxicity (DLT) is used for dose escalation in stage 1 and a time to event endpoint is used
for dose allocation in stage 2. The overall goal is to estimate the dose combination region
associated with the highest median time to progression (TTP) among doses along the MTD
curve. Conditional escalation with overdose control (EWOC) is used in stage 1 to allocate
dose combinations to subsequent cohorts of patients and estimate the MTD. Stage 2 starts
by allocating a first cohort of patients to dose combinations equally spaced along the MTD
curve, and then allocates subsequent cohorts of patients to dose combinations likely to have
high posterior median TTP using adaptive randomization. We perform extensive simulation
studies to evaluate the operating characteristics of our method.
Keywords: Adaptive randomization, Continuous doses, Drug combinations, Escalation with
overdose control, Phase I/II trial
1 Introduction
In cancer phase I/II clinical trials, the main goal is to identify a safe dose that maximizes the
treatment efficacy. In single-agent settings with binary or time to event endpoints where efficacy
is observed relatively fast (e.g. one or two cycles of therapy), one-stage sequential designs where
the joint probability of toxicity and efficacy is sequentially updated after each cohort of patients
are usually employed (see e.g. [1, 2, 3, 4, 5, 6, 7] for binary endpoints, and [8] for time to event
endpoints). This methodology has been extended to accommodate combination of drugs of any
kind (see e.g. [9, 10] for binary endpoints and [8] for time to event endpoints), and proceed in a
similar fashion as the methods referenced for single-agent.
In cases where efficacy is not ascertained in a short period of time, it is frequent to employ
two-stage designs where, a maximum tolerated dose (MTD) set is first selected, and then tested
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for efficacy in a second stage with possibly a different population of patients than the one used
in the first stage. This approach has been discussed by [11, 12, 13]. For drug combination trials,
methodology for these type of two-stage designs have been proposed for binary efficacy endpoints
(see e.g. [14, 15]).
One characteristic that most of these methods have in common is that they only recommend a
single MTD either at the end of the phase I trial, or at the end of the first stage in a phase I/II
trial. However, even if the recommended dose that will be tested for efficacy is indeed a valid MTD,
there could be another MTD with higher efficacy, making the MTD recommended in the first place
non-optimal.
In this article, we present a two-stage design for drug combination trials
In this article, we extend the work from [15] by proposing a two-stage design for drug combi-
nations trials with time to event efficacy endpoint in the second stage and continuous dose levels
when treatment efficacy is evaluated after three or more cycles of therapy. In the first stage, the
dose finding method proposed by [16] is used to estimate the MTD curve. In the second stage,
a Bayesian adaptive design that starts allocating a first cohort of patients to dose combinations
equally spaced along the MTD curve, and then allocates subsequent cohorts of patients to dose
combinations likely to have high posterior median TTP using adaptive randomization. To allow for
different shapes in the median TTP curve, we employ a flexible family of cubic splines to model the
dose - median TTP relationship. Adaptive randomization is sequentially used after a pre-defined
time period to minimize the number of patients allocated at sub-therapeutic dose levels. At the
end of the trial, the dose combination within the MTD with highest a posteriori median TTP is
selected and recommended for further phase II or III studies.
The manuscript is organized as follows. In section 2, we review the first stage of the proposed
phase I/II trial previously described in [16, 15]. In section 3, we describe the second stage of the
design. In section 4, we illustrate the methodology with the phase I/II drug combination trial of
cisplatin and cabazitaxel in patients with prostate cancer with visceral metastasis where time to
progression is a secondary endpoint. The goal in this trial is to find a tolerable dose combination
with highest TTP median. A discussion of the approach and final remarks are included in Section
5.
2 Phase I/II Trial: Stage 1
2.1 Model
Following [16], consider the generic form of a dose-toxicity model
P (T = 1|x, y) = F (η0 + η1x+ η2y + η3xy), (1)
where T = 1 represents an observed DLT at the dose combination (x, y), T = 0 otherwise, x ∈
[Xmin, Xmax] is the dose level of agent A, y ∈ [Ymin, Ymax] is the dose level of agent B and F (.) is a
known cumulative distribution function. We assume that the dose combinations are continuous and
standardized to be in the interval [0,1], the interaction parameter η3 > 0, and η1, η2 > 0 in order to
guarantee that the probability of DLT increases with the dose of any agent when the other one is
held constant.
The MTD is defined as any dose combination (x∗, y∗) such that
P (T = 1|x∗, y∗) = θ. (2)
As described in [16], we reparameterize equation (1) as follows. Let ρ10, the probability of DLT
when the levels of drugs A and B are 1 and 0, respectively, ρ01, the probability of DLT when the
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levels of drugs A and B are 0 and 1, respectively, ρ00, the probability of DLT when the levels of
drugs A and B are both 0. Hence, it is possible to show that MTD takes the form
C =
{
(x∗, y∗) : y∗ =
[
(F−1(θ)− F−1(ρ00))− (F−1(ρ10)− F−1(ρ00))x∗
]
÷
[
(F−1(ρ01)− F−1(ρ00))η3x∗
]}
.
(3)
We assume that ρ10, ρ01 and η3 are independent a priori with ρ01 ∼ beta(a1, b1), ρ10 ∼ beta(a2, b2),
and conditional on (ρ01, ρ10), ρ00/min(ρ01, ρ10) ∼ beta(a3, b3). The prior distribution on the interac-
tion parameter η3 is a gamma distribution with mean a/b and variance a/b
2. Let Dn = {(xi, yi, Ti)}
be the data gathered after enrolling n patients. The posterior distribution of the model parameters
is
pi(ρ00, ρ10, ρ01, η3) ∝
n∏
i=1
G((ρ00, ρ10, ρ01, η3;xi, yi))
Ti
× (1−G(ρ00, ρ10, ρ01, η3;xi, yi))1−Ti
× pi(ρ01)pi(ρ10)pi(ρ00|ρ01, ρ10)pi(η),
(4)
where
G(ρ00, ρ10, ρ01, η3;xi, yi) = F (F
−1(ρ00) + (F−1(ρ10)−
F−1(ρ00))xi + (F−1(ρ01)− F−1(ρ00))yi + η3xiyi).
(5)
Note that the operating characteristics of this stage are evaluated using informative prior dis-
tributions (see [15]).
2.2 Trial Design
Dose escalation / de-escalation proceeds using the same algorithm described in [16]. It is based on
escalation with overdose control (EWOC) where, after each cohort of enrolled patients, the posterior
probability of overdosing the next cohort of patients is bounded by a feasibility bound α, see e.g.
[17, 18, 19, 20]. In a cohort with two patients, the first one would receive a new dose of agent A
given that the dose y of agent B that was previously assigned. The other patient would receive a
new dose of agent B given that dose x of agent A was previously assigned. Using EWOC, these
new doses are at the α-th percentile of the conditional posterior distribution of the MTDs. The
algorithm continues until the maximum sample size is reached or until the trial is stopped for safety.
A detailed description of this algorithm can be found in [16]. At the end of the trial, the MTD
curve is estimated as
Cest =
{
(x∗, y∗) : y∗ =
[
(F−1(θ)− F−1(ρ̂00))− (F−1(ρ̂10)− F−1(ρ̂00))x∗
]
÷[
(F−1(ρ̂01)− F−1(ρ̂00))η̂3x∗
]}
,
(6)
where ρ̂00, ρ̂10, ρ̂01, η̂ are the posterior medians given the data Dn. This method has been extensively
studied by [16] and hence we only present the operating characteristics in the context of the CisCab
trial described in section 4.
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3 Phase I/II Trial: Stage 2
3.1 Model
Let x be a dose of drug A such that (x, y) ∈ Cest. Also, assume that x is standardized to in the
interval [0,1]. We model the time to progression as a Weibull distribution with probability density
function
f(t;x) =
k
λ(x;ψ)
(
t
λ(x;ψ)
)k−1
exp
(
− t
λ(x;ψ)
)k
. (7)
The median TTP is
Med(x) = λ(x;ψ)(log 2)
1
k . (8)
A flexible way of modeling the median TTP along the MTD curve is through the use of the
cubic spline function
λ(x;ψ) = exp
(
β0 + β1x+ β2x
2 +
k∑
j=3
βj(x− κj)3+
)
, (9)
where ψ = (β,κ), with β = (β0, . . . , βk) and κ = (κ3, . . . , κk), being κ3 = 0. Let Dm =
{(xi, ti, δi), i = 1 . . . ,m} be the data after enrolling m patients in the trial where t represents
the TTP or last follow-up, and δ the censoring status, and let pi(ψ, k) be the joint prior density on
the parameter vector ψ and k. The posterior distribution is
pi(ψ, k|Dm) ∝ pi(ψ, k)
m∏
i=1
[
k
λ(xi;ψ)
(
ti
λ(xi;ψ)
)k−1]δi
× exp
(
− ti
λ(xi;ψ)
)k
.
(10)
Let Medx be the median TTP at dose combination x and let Med0 be the median TTP of the
standard of care treatment. We propose an adaptive design in order to test the hypothesis
H0 : Medx ≤ Med0 for all x vs.
H1 : Medx > Med0 for some x.
(11)
3.2 Trial Design
i We first treat n1 patients at dose combinations x1, . . . , xn1 , which are equally spaced along
the estimated MTD curve Cest.
ii Obtain Bayes estimates of ψˆ and kˆ, of ψ and k given the data Dn1 using equation (10). Note
that prior to obtaining the Bayes estimates, patients that have not progressed are censored.
iii Generate n2 dose combinations from the standardized density Mˆed(x) = λ(x; ψˆ)(log 2)
1
kˆ and
assign them to the next n2 patients.
iv Repeat steps (ii) and (iii) until a total of n patients have been enrolled to the trial subject to
pre-specified stopping rules.
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Decision Rule: At the end of the trial, we reject the null hypothesis if Maxx{P (Med(x;ψi) >
Med0|Dn,i)} > δu, where δu is a design parameter.
Stopping Rule (Futility): For ethical reasons and to avoid treating patient at sub-therapeutic
dose levels, we will stop the trial for futility if there is strong evidence that none of the dose
combinations are promising, i.e., Maxx{P (Med(x;ψi) > Med0|Dn,i)} < δ0, where δ0 is a design
parameter.
Stopping Rule (Efficacy): For ethical reasons, if the investigator considers there is enough evi-
dence in favor of one or more dose combinations being tested, and no further patients need to be
enrolled, the trial can be terminated if Maxx{P (Med(x;ψi) > Med0|Dn,i)} > δ1, where δ1 ≥ δu is
a study parameter and the dose combination
xopt = arg maxv{P (Med(v;ψi) > Med0|Dn,i)} is selected for further randomized phase II or phase
III clinical trials.
3.2.1 Design Operating Characteristics
We assess the operating characteristics of the proposed design by assuming that λ(x;ψ) is a cubic
spline with two knots placed between 0 and 1. This class of modeling is very flexible and is
able to adapt to scenarios where the median TTP is either constant or skewed toward one of the
edges. Vague priors are placed on the model parameters by assuming β ∼ N(µ, σ2I6), where
µ = {0, 0, 0, 0, 0, 0} and σ2 = 100, and (κ4, κ5) ∼ Unif{(u, v) : 0 ≤ u < v ≤ 1}. Note that the
parameters of the prior distribution of β are always the same regardless the value of Med0.
For each scenario favoring the alternative hypothesis, we estimate the Bayesian power, which is
defined as
Power ≈ 1
M
M∑
i=1
I[Maxx{P (Med(x;ψi) > Med0|Dn,i)} > δu], (12)
where
P (Med(x;ψi) > Med0|Dn,i) ≈
1
L
L∑
j=1
I
[
Med(x;ψi,j) > Med0
]
(13)
and ψi,j is the j-th MCMC sample for the i-th trial.
For scenarios favoring the null hypothesis, (12) is the estimated Bayesian type-I error probability.
The optimal dose from the i-th trial is defined as
xopti = arg maxv{P (Med(v;ψi) > Med0|Dn,i)}. (14)
We also report the estimated TTP median by replacing ψ in (8) by the average posterior median
across all simulated trials. Last, we also report the mean posterior probability of Medx > Med0 for
any dose combination x.
4 Application to the CisCab Phase I/II Trial
We illustrate the methods proposed in sections 2 and 3 with a phase I/II trial referred as the
“CisCab trial” where TTP is a secondary endpoint of the trial. We are motivated by a phase I trial
published by [21], that combines cisplatin and cabazitaxel in patients with advanced solid tumors,
where the MTD was established at 15/75 mg/m2. In a first part of this motivating trial, doses were
escalated according to a standard “3+3” design and no DLTs were observed at dose combination
which was found to be the MTD. During the second part of the trial, 15 additional patient were
treated at the MTD and 2 DLTs were observed. In total, 18 patients were treated at the MTD.
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Considering these results, there may be other active dose combinations that are tolerable and
active in prostate cancer with visceral metastasis. The CisCab trial considers doses that range from
10 to 25 mg/m2 for cabazitaxel, and from 50 to 100 mg/m2 for cisplatin, that will be administered
intravenously. In a first stage, the CisCab trial will enroll 30 patients in order to obtain the MTD
curve. This stage of the design proceeds as explained in section 3, with a target probability of DLT
θ = 0.33, and a logistic link fuction F (.) in equation (1). The starting dose combination for the first
cohort of two patients is 15/75 mg/m2, and DLTs are to be resolved within 1 cycle of treatment
(3 weeks). Prior distributions are calibrated such that the prior mean probability of DLT at dose
combination 15/75 mg/m2 equals θ (see [15]). The operating characteristics of this first stage are
obtained by simulating 1000 trials replicates following [16].
In Figures 1 and 2 we show the true and estimated MTD curves obtained with equation (6)
respectively in two different scenarios . In the scenario presented in Figure 1, the true MTD curve
passes through the dose combination 15/75 mg/m2, whereas in the scenario presented in Figure 2,
the true MTD curve is significantly above the dose combination 15/75 mg/m2. In both scenarios
the estimated MTD curves are very close to the true MTD curves. These results are supported
the pointwise average bias shown in Figures 6 and 7. In these scenarios, the pointwise average bias
fluctuates between -0.01 and 0.01, and between -0.05 and 0.1 respectively. In terms of safety, the
percent of trials with DLT rate above θ+0.1 is below 10% in both scenarios with average number of
DLTs of 34% and 27%. We also present results regarding percent correct recommendation. These
results are shown in Figures 8 and 9 and overall we observe that, in the two proposed scenarios, the
percent of correct recommentation is between 70% and 100% in the scenario where the MTD passes
through the dose combination 15/75 mg/m2, and between 50% and 100% in the scenario where
the MTD is above the dose combination 15/75 mg/m2. Note that these results depend on a design
parameter p that takes the values 0.05 and 0.1and that states how strict we are when considering a
correct recommendation, being p = 0.1 less strict than p = 0.05. The true parameter values as well
as the safety results are shown in Table 1.
In the second stage, 30 additional patients are enrolled to identify the dose combinations along
the MTD curve from the first stage, that are likely to have high posterior median TTP. The TTP
of the standard care of treatment, which is necessary to perform the hypothesis testing procedure,
is chosen to be 4 months since this is the radiographic median TTP in a placebo arm in a previous
phase III trial. We present simulations based on 4 scenarios supporting the alternative hypothesis
and 4 scenarios favoring the null hypothesis. For each scenario favoring the alternative hypothesis,
effect sizes of 1.5 and 2 months and accrual rates of 1 and 2 patients per month will be used. In
order to correctly assess the operating characteristics of the design, the 4 scenarios will have the
same TTP of the standard treatment of care, the same effect size and the same accrual rate. This
way, the only difference between scenarios will be the shape of the TTP median curve, allowing to
see the behavior of the design when the optimal dose level is located at different dose levels.
The simulations were carried out using the model and prior distributions presented in sections
3.1 and 3.2.1 respectively, with n1 = 10, n2 = 5, δu = 0.8 and δu = 0.9.
In Figures 3 and 4 we present the 4 simulated scenarios favoring the alternative hypothesis with
effect sizes of 1.5 and 2 months respectively, and an accrual rate of 1 patient per month. In Figure
5 we present the same 4 simulated scenarios favoring the null hypothesis with an accrual rate of 1
patient per month. Results for the same 4 simulated scenarios with an accrual rate of 2 patients per
month can be found in Figures 10, 11 and 12 in the appendix. In these figures, we present the true
median TTP curve, the null medial TTP, as well as the average recommended dose, the estimated
median TTP curve and the posterior probability that the median TTP at a dose level x is greater
than the null median TTP as measurements of efficiency. Overall, we observe that the design
captures the shape of the median TTP curve. However, the estimated median TTP curve is not
a very informative measurement of efficiency since we are using adaptive randomization and hence
much more patients are allocated in certain dose levels. The efficiency measurement we believe
6
is more interesting is the posterior probability that the median TTP at a dose level x is greater
than the TTP of the standard treatment of care. In all figures, we observe that the recommended
optimal dose is very close to the true optimal dose regardless the shape of the TTP median, the
effect size or the accrual rate.
In Table 2, we present the Bayesian power, the probability of the type-I error as well as the
probability of type-I + type-II errors for different effect sizes and different accrual rates. With an
accrual rate of 1 patient per month, the probability of type-I error remains between 0.104 and 0.227
when δu = 0.8 and between 0.235 and 0.308 when δu = 0.9. However, with an accrual rate of 2
patients per month, the probability of type-I error is much smaller overall and it remains between
0.035 and 0.107 when δu = 0.8 and between 0.008 and 0.048 when δu = 0.9.
In terms of power, with effect size of 1.5 months and an accrual rate of 1 patient per month,
we observe that the power remains between 0.706 and 0.924 when δu = 0.8 and between 0.52 and
0.844 when δu = 0.9. If the effect size increases up to 2 months and maintaining the same accrual
rate, the power remains between 0.931 and 0.972 when δu = 0.8 and between 0.846 and 0.932 when
δu = 0.9. In contrast, if we fix the accrual rate to 2 patient per month, we observe that overall the
power decreases considerately. With an effect size of 1.5 months, the power remains between 0.522
and 0.824 when δu = 0.8 and between 0.338 and 0.674 when δu = 0.9. If the effect size increases
up to 2 months and maintaining the same accrual rate, the power remains between 0.766 and 0.92
when δu = 0.8 and between 0.615 and 0.829 when δu = 0.9.
Because it is difficult to find the right balance between power and type-I error, and since it
is not unusual to find probabilities of type-I error between 0.15 - 0.2 in phase II trials of these
characteristics where we try a large set of doses with a small sample size, we evaluate the sum of
the probabilities of type-I error and type-II errors. In general, a design where the sum of these two
probabilities is above 0.3 is not advisable. In our proposal, with effect size of 1.5 months and an
accrual rate of 1 patient per month, the sum of the probabilities of type-I error and type-II error
remains between 0.235 and 0.416 when δu = 0.8 and between 0.264 and 0.523 when δu = 0.9. If
the effect size increases up to 2 months and maintaining the same accrual rate, the sum of the
probabilities of type-I error and type-II error remains between 0.15 and 0.256 when δu = 0.8 and
between 0.123 and 0.198 when δu = 0.9. If we fix the accrual rate to 2 patient per month, with
an effect size of 1.5 months, the sum of the probabilities of type-I error and type-II error remains
between 0.283 and 0.513 when δu = 0.8 and between 0.374 and 0.67 when δu = 0.9. If the effect size
increases up to 2 months and maintaining the same accrual rate, the the sum of the probabilities
of type-I error and type-II error remains between 0.17 and 0.287 when δu = 0.8 and between 0.219
and 0.403 when δu = 0.9.
If we focus one the sum of the probabilities of type-I error and type-II error, we observe that
with an effect size of 1.5 months we observe a lot of values above our 0.3 threshold regardless the
accrual rate, which is normal since the original design’s primary endpoint was not the TTP median
and it is not sufficiently powered for this effect size. In contrast, with an effect size of of 2 months,
we observe that if δu = 0.8 all the values are below our 0.3 threshold regardless the accrual rate
and if δu = 0.9, only one scenario with an accrual rate of 2 patients per month has a value above
the threshold.
In Table 3, we present the probability of early stopping and average sample size at the moment
of stopping in scenarios favoring the null hypothesis. Overall, we observe that an accrual rate of 2
patients per month produces a slight increase in the probability of early stopping and a decrease
between 1 and 2 patients in the average sample size at the moment of stopping with respect to
using an accrual rate of 1 patient per month.
Even though it is not listed in the operating characteristics, in Figure 13 we show the dose
allocation distribution in the four scenarios with the different effect sizes and accrual rates. In
scenario 1, we correctly allocate more than 71% of the patients in doses that are above the TTP
of the standard treatment of care. In scenarios 2, 3 and 4 we correctly allocate more than 65%,
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77% and 60% of the patients respectively in dose above the TTP of the standard treatment of care.
Note that from these distributions we excluded the first n1 doses which are automatically allocated
in doses equally spaced along the MTD.
We also implement scenarios 1 and 2 when the TTP of the standard treatment of care is higher
than 4 months. More precisely we tuned scenarios 1 and 2 to have effect sizes of 2 months but the
TTP of the standard treatment of care is now 8 months. We used accrual rates of 2 and 3 patients
per month and we observed values of power, type-I error and sum of type-I and type-II errors that
are consistent with the values presented in Table 2. These results are showed in Table 4.
Hence, we conclude that our design has overall good operating characteristics with accrual rates
that are considered realistic in practice.
5 Conclusions
In this paper we propose a Bayesian adaptive two-stage design for cancer phase I/II trials using
drug combinations with continuous dose levels and TTP endpoint. We are motivated by a phase
I trial published by [21], that combines cisplatin and cabazitaxel in patients with prostate cancer
with visceral metastasis, where the MTD was established at 15/75 mg/m2. In a first part of this
motivating trial, doses were escalated according to a standard “3+3” design and no DLTs were
observed at dose combination which was found to be the MTD. During the second part of the
trial, 15 additional patient were treated at the MTD and 2 DLTs were observed, and in total 18
patients were treated at the MTD. However, considering these results, there may be other active
dose combinations that are tolerable and active in prostate cancer with visceral metastasis.
In the first stage of the design a logistic model is used to model the probability of DLT. The
dose escalation algorithm proceeds by using EWOC as described in [16]. At the end of this stage,
an estimate of the MTD curve is obtained. In the second stage we model the median TTP along
the MTD curve using a weibull model and incorporating a cubic spline through the scale parameter
of the model. In this stage of the design a hypothesis test is performed where the null hypothesis
states that the median TTP corresponding to all dose levels is below or equal to a TTP of the
standard treatment of care. On the other hand, the alternative hypothesis states that the median
TTP corresponding to some dose levels is above the TTP of the standard treatment of care. The
dose escalation in the second stage proceeds by first allocating n1 patients in dose levels equally
spaced along the MTD curve. Subsequent patients are allocated in cohorts of n2 patients in doses
with higher posterior probability of having a median TTP greater TTP of the standard treatment
of care using adaptive randomization.
Regarding the first stage, we studied the operating characteristics in 2 scenarios. In the one
scenario the true MTD curve passes through the dose combination 15/75 mg/m2, whereas in the
other scenario the true MTD curve is significantly above the dose combination 15/75 mg/m2. We
found that this stage of the trial is safe and has good operating characteristics in terms of pointwise
bias and percent selection. Note that the operating characteristics of this stage were evaluated
using informative prior distributions as commented in section 4.
With respect to the second stage, we studied the operating characteristics of the design in 4
scenarios in which the null median TTP is the same and so is the effect size and accrual rate and
hence the only difference between them is the median TTP curve shape that places the dose level
with highest TTP at a different location in each scenario. These 4 scenarios were implemented with
effects sizes of 1.5 and 2 months, and accrual rates of 1 patient and 2 patients per month, which
are considerate reasonable in practice. In general, we observed good operating characteristics in
terms of optimal dose recommendation and sum of the probabilities of type-I and type-II errors as
main measurements of efficiency. Scenarios 1 and 2 were also implemented when the TTP of the
standard treatment of care is higher than 4 months. More precisely we tuned scenarios 1 and 2 to
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have effect sizes of 2 months but the TTP of the standard treatment of care is now 8 months. We
used accrual rates of 2 and 3 patients per month and we observed values of power, type-I error and
sum of type-I and type-II errors that are consistent with the values presented in Table 2.
Note that the operating characteristics in the second stage were evaluated under vague prior
distributions of the model parameters and no efficacy profiles of single agent trials we used a priori.
A limitation of this methodology is that the uncertainty of the estimated MTD curve in stage I
is not taken into account in stage II of the design. This implies that the MTD curve is not updated
during the second stage, which is a limitation since patients in stage II may come from a different
population with respect to patients in the first stage. As pointed out by [15], an alternative design
for this particular paper would account for first-, second- and third-cycle DLT in addition to efficacy
outcome at each cycle. Also, the nature of DLT (reversible versus non-reversible) should be taken
into account since patients with a reversible DLT are usually treated for that side effect and kept in
the trial with dose reduction in subsequent cycles. Hence, for drug combinations with continuous
dose levels and three cycles of therapy, another layer of model complexity would be introduced but
such designs are beyond the scope of this paper and are subjects of future research. In addition, we
note that a continuous monitoring of the rate of DLT in stage II is also carried out as discussed in
[15] so that the trial will stop early if there is evidence of an excessive rate of DLT.
6 Software and data sharing
The R code and data that support the findings of this study are available from the corresponding
author upon request.
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Figure 1: True and estimated MTD curve for scenario 1 in the first stage of the design.
Figure 2: True and estimated MTD curve for scenario 2 in the first stage of the design.
Table 1: True parameter values for ρ00, ρ01, ρ10, η and θ as well as safety results for the two simulated
scenarios of the first stage where EWOC is employed.
Scenario 1 Scenario 2
ρ00 1e-5 1e-8
ρ01 0.10 0.00005
ρ10 0.10 0.00008
η 20 20
θ 0.33333 0.33333
Average number of DLTs 0.34 0.27
Number of trials with DLT rate > θ + 0.1 7.30 0.00
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Figure 3: True and estimated TTP medians under four scenarios favoring the alternative hypothesis
with effect size of 1.5 months and accrual rate of 1 patient per month.
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Table 2: Bayesian power, type I error probability and type-I + type-II error probability in four
scenarios with effect sizes of 1.5 and 2 months, and accrual rates of 1 and 2 patients per month.
Power
(effect size
of 1.5 months)
Power
(effect size
of 2 months)
Probability of
type-I error
Probability of
type-I + type-II
errors (effect
size of 1.5 months)
Probability of
type-I + type-II
errors (effect
size of 2 months)
δu δu δu δu δu
Scenario
Accrual
rate
0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9
1
1
0.924 0.844 0.971 0.927 0.227 0.121 0.303 0.277 0.256 0.194
2 0.706 0.520 0.972 0.920 0.122 0.043 0.416 0.523 0.150 0.123
3 0.904 0.808 0.973 0.932 0.139 0.072 0.235 0.264 0.166 0.140
4 0.796 0.646 0.931 0.846 0.104 0.044 0.308 0.398 0.173 0.198
1
2
0.824 0.674 0.920 0.829 0.107 0.048 0.283 0.374 0.187 0.219
2 0.522 0.338 0.865 0.755 0.035 0.008 0.513 0.670 0.170 0.253
3 0.759 0.598 0.896 0.790 0.068 0.024 0.309 0.426 0.172 0.234
4 0.623 0.445 0.766 0.615 0.053 0.018 0.430 0.573 0.287 0.403
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Figure 4: True and estimated TTP medians under four scenarios favoring the alternative hypothesis
with effect size of 2 months and accrual rate of 1 patient per month.
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Table 3: Probability of early stopping under the null hypothesis in four scenarios with accrual rates
of 1 and 2 patients per month.
Probability of
early stopping
Average sample size
δ0 δ0
Scenario
Accrual
rate
0.10 0.15 0.20 0.10 0.15 0.20
1
1
0.164 0.266 0.355 19.94 18.14 16.92
2 0.121 0.252 0.390 17.44 15.41 13.76
3 0.234 0.358 0.506 20.17 17.67 16.13
4 0.264 0.417 0.554 19.79 17.75 16.17
1
2
0.307 0.457 0.576 18.55 16.95 15.99
2 0.270 0.452 0.611 15.64 13.63 12.20
3 0.410 0.611 0.740 19.02 16.94 15.01
4 0.421 0.590 0.731 18.41 16.44 14.67
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Figure 5: True and estimated TTP medians under four scenarios favoring the null hypothesis with
an accrual rate of 1 patient per month.
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Appendix
In this section we display Figures that contain information regarding operating characteristics of
the design and support the conclusions obtained along the manuscript.
Figure 6: Pointwise average bias for scenario 1 in the first stage of the design.
Figure 7: Pointwise average bias for scenario 2 in the first stage of the design.
Figure 8: Percent of correct recommendation for scenario 1 in the first stage of the design.
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Figure 9: Percent of correct recommendation for scenario 2 in the first stage of the design.
Figure 10: True and estimated TTP medians under four scenarios favoring the alternative hypothesis
with effect size of 1.5 months and accrual rate of 2 patients per month.
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Figure 11: True and estimated TTP medians under four scenarios favoring the alternative hypothesis
with effect size of 2 months and accrual rate of 2 patients per month.
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Table 4: Bayesian power, type I error probability and type-I + type-II error probability in two
scenarios with effect size of 2 months, and accrual rates of 2 and 3 patients per month.
Power
(effect size
of 2 months)
Probability of
type-I error
Probability of
type-I + type-II
errors (effect
size of 2 months)
δu δu δu
Scenario
Accrual
rate
0.8 0.9 0.8 0.9 0.8 0.9
1
2
0.836 0.677 0.162 0.080 0.326 0.403
2 0.742 0.577 0.121 0.052 0.379 0.475
1
3
0.824 0.639 0.167 0.081 0.343 0.442
2 0.747 0.572 0.109 0.046 0.362 0.474
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Figure 12: True and estimated TTP medians under four scenarios favoring the null hypothesis with
an accrual rate of 2 patient per month.
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Figure 13: Dose allocation density across scenarios with effect sizes (ES) of 1.5 and 2 months and
accrual rates (AR) of 1 and 2 patients per months.
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